Long-Term Adherence and Drug Utilisation Patterns Among New Users of Anti-Hyperlipidemic Monotherapy: Development of
Xuechun Li1, Eelko Hak1, Jens H J Bos1
1Unit PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.
Journal of Evaluation in Clinical Practice
|February 19, 2026
Summary
Simvastatin users showed the highest adherence and continuation rates for hyperlipidemia management. Older age, female sex, and diabetes medication use were linked to better adherence, informing personalized cardiovascular disease prevention strategies.
Area of Science:
- Cardiology
- Pharmacology
- Real-world evidence
Background:
- Long-term adherence and drug patterns are crucial for managing hyperlipidemia.
- Existing evidence on these patterns remains limited.
Purpose of the Study:
- To assess long-term adherence and drug usage patterns of anti-hyperlipidemic monotherapy.
- To identify risk factors associated with adherence and drug utilization.
- To develop risk prediction models for hyperlipidemia treatment outcomes.
Main Methods:
- Retrospective inception cohort study using the IADB.nl dispensing database.
- Inclusion of new users of specific anti-hyperlipidemic monotherapies (simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, fibrates).
- Approximately 10-year follow-up with logistic regression for risk prediction models.
Main Results:
- Simvastatin users exhibited high adherence (83.6%-90.2%) and the highest continuation rate (39.2%).
- Older age (≥40), female sex, and concurrent diabetes medication use were associated with better adherence and continuation.
- Male patients showed lower adherence but higher continuation; antiparkinson drug users had lower continuation.
Conclusions:
- Simvastatin demonstrated superior adherence and continuation compared to other monotherapies.
- Older patients, females, and those on diabetes medications benefit from improved adherence.
- Findings support personalized strategies for optimizing cardiovascular disease prevention in hyperlipidemia management.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
01:29Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
328
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
328
01:29Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
01:12Analysis of Population Pharmacokinetic Data
829
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
829